AU2013345107B2 - Heteroaromatic compounds as PI3 kinase modulators and methods of use - Google Patents

Heteroaromatic compounds as PI3 kinase modulators and methods of use Download PDF

Info

Publication number
AU2013345107B2
AU2013345107B2 AU2013345107A AU2013345107A AU2013345107B2 AU 2013345107 B2 AU2013345107 B2 AU 2013345107B2 AU 2013345107 A AU2013345107 A AU 2013345107A AU 2013345107 A AU2013345107 A AU 2013345107A AU 2013345107 B2 AU2013345107 B2 AU 2013345107B2
Authority
AU
Australia
Prior art keywords
mmol
compound
cancer
pct
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013345107A
Other languages
English (en)
Other versions
AU2013345107A1 (en
Inventor
Ning Xi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of AU2013345107A1 publication Critical patent/AU2013345107A1/en
Application granted granted Critical
Publication of AU2013345107B2 publication Critical patent/AU2013345107B2/en
Assigned to CALITOR SCIENCES, LLC, NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED reassignment CALITOR SCIENCES, LLC Request for Assignment Assignors: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
Assigned to CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD. reassignment CALITOR SCIENCES, LLC Request for Assignment Assignors: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED, CALITOR SCIENCES, LLC
Assigned to SUNSHINE LAKE PHARMA CO., LTD. reassignment SUNSHINE LAKE PHARMA CO., LTD. Request for Assignment Assignors: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013345107A 2012-11-14 2013-11-10 Heteroaromatic compounds as PI3 kinase modulators and methods of use Active AU2013345107B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726139P 2012-11-14 2012-11-14
US61/726,139 2012-11-14
PCT/US2013/069366 WO2014078211A1 (en) 2012-11-14 2013-11-10 Heteroaromatic compounds as pi3 kinase modulators and methods of use

Publications (2)

Publication Number Publication Date
AU2013345107A1 AU2013345107A1 (en) 2015-04-30
AU2013345107B2 true AU2013345107B2 (en) 2016-02-25

Family

ID=50681898

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013345107A Active AU2013345107B2 (en) 2012-11-14 2013-11-10 Heteroaromatic compounds as PI3 kinase modulators and methods of use

Country Status (15)

Country Link
US (1) US9926324B2 (enExample)
EP (2) EP2919784B1 (enExample)
JP (1) JP6268183B2 (enExample)
KR (1) KR102148679B1 (enExample)
CN (1) CN104755085B (enExample)
AU (1) AU2013345107B2 (enExample)
BR (1) BR112015006726B1 (enExample)
CA (1) CA2889346C (enExample)
ES (1) ES2661380T3 (enExample)
MY (1) MY180641A (enExample)
RU (1) RU2665036C9 (enExample)
SG (1) SG11201502725TA (enExample)
TW (1) TWI574962B (enExample)
WO (1) WO2014078211A1 (enExample)
ZA (1) ZA201502575B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
EP3159342B1 (en) * 2014-06-17 2020-08-05 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
CN105503877A (zh) 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途
SI3233839T1 (sl) * 2014-12-19 2019-12-31 Janssen Pharmaceutica Nv Heterociklil vezani derivati imidazopiridazina kot inhibitorji PI3Kbeta
JP6568588B2 (ja) * 2014-12-19 2019-08-28 ヤンセン ファーマシューティカ エヌ．ベー． ＰＩ３Ｋβ阻害剤としてのイミダゾピリダジン誘導体
JP7149854B2 (ja) * 2016-06-16 2022-10-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
JP2019534266A (ja) 2016-10-14 2019-11-28 江蘇恒瑞医薬股▲ふん▼有限公司 ５員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用
US11629146B2 (en) * 2016-11-28 2023-04-18 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity
CN108164525B (zh) * 2016-12-08 2020-09-08 沈阳药科大学 一种抗肿瘤化合物的制备方法和用途
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
FR3064364A1 (fr) * 2017-03-27 2018-09-28 S.P.C.M. Sa Methode de dosage de polymeres cationiques
PH12022500017A1 (en) 2020-04-29 2023-08-14 De Shaw Res Llc PI3K-a INHIBITORS AND METHODS OF USE THEREOF
WO2023039532A1 (en) * 2021-09-10 2023-03-16 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
WO2023220131A2 (en) * 2022-05-10 2023-11-16 Relay Therapeutics, Inc. PI3Kα INHIBITORS AND METHODS OF USE THEREOF
CN120737113B (zh) * 2025-09-03 2025-11-21 湖北师范大学 一种三唑并哒嗪类化合物区域选择性c3-h炔基化的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163489A1 (en) * 2007-12-19 2009-06-25 Shon Booker Inhibitors of PI3 kinase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2036924C1 (ru) * 1989-01-31 1995-06-09 Такеда Кемикал Индастриз ЛТД Способ получения производных имидазо (1,2-b)пиридазина или их солей и производные имидазо (1,2-b)пиридазина или их соли
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
WO1995015373A2 (en) 1993-11-30 1995-06-08 Mcgill University Inhibition of dna methyltransferase
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
WO1998054313A2 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
EP1173562A2 (en) 1999-05-03 2002-01-23 Methylgene, Inc. Inhibition of histone deacetylase
KR101026205B1 (ko) 1999-11-23 2011-03-31 메틸진 인코포레이티드 히스톤 디아세틸라제의 억제제
EP1438404A2 (en) 2000-03-24 2004-07-21 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
CA2404002A1 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
AU2001264595A1 (en) * 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US7282608B2 (en) 2002-10-17 2007-10-16 Methylgene, Inc. Inhibitors of histone deacetylase
EP1663953A1 (en) 2003-09-24 2006-06-07 Methylgene, Inc. Inhibitors of histone deacetylase
KR101258504B1 (ko) 2004-03-26 2013-04-26 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
WO2006010264A1 (en) 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
ES2761180T3 (es) * 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
RU2009107705A (ru) * 2006-08-04 2010-09-10 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение и его применение
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
AR071523A1 (es) * 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
JP5951600B2 (ja) * 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US9284334B2 (en) 2011-05-19 2016-03-15 Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii Macrocyclic compounds as protein kinase inhibitors
WO2012174312A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
KR101274986B1 (ko) 2011-07-27 2013-06-17 한국과학기술원 이미다조피리딘 유도체, 이를 포함하는 ＰＩ3Ｋ 및/또는 ｍＴＯＲ 저해제용 약학 조성물 및 ＰＩ3Ｋ 및/또는 ｍＴＯＲ과 연관된 질환 치료용 약학 조성물
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163489A1 (en) * 2007-12-19 2009-06-25 Shon Booker Inhibitors of PI3 kinase

Also Published As

Publication number Publication date
RU2015116102A (ru) 2017-01-10
RU2665036C9 (ru) 2018-11-12
RU2665036C2 (ru) 2018-08-27
ZA201502575B (en) 2016-11-30
EP2919784A1 (en) 2015-09-23
MY180641A (en) 2020-12-04
BR112015006726B1 (pt) 2021-11-23
AU2013345107A1 (en) 2015-04-30
TW201422615A (zh) 2014-06-16
JP6268183B2 (ja) 2018-01-24
BR112015006726A2 (pt) 2017-08-22
ES2661380T3 (es) 2018-03-28
EP3299019B1 (en) 2019-10-09
CA2889346C (en) 2018-09-25
SG11201502725TA (en) 2015-05-28
TWI574962B (zh) 2017-03-21
HK1210956A1 (en) 2016-05-13
EP2919784A4 (en) 2016-07-06
KR20150083833A (ko) 2015-07-20
EP3299019A1 (en) 2018-03-28
CN104755085A (zh) 2015-07-01
JP2015536994A (ja) 2015-12-24
US9926324B2 (en) 2018-03-27
CN104755085B (zh) 2018-05-01
WO2014078211A1 (en) 2014-05-22
KR102148679B1 (ko) 2020-08-27
CA2889346A1 (en) 2014-05-22
US20140134133A1 (en) 2014-05-15
EP2919784B1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
AU2013345107B2 (en) Heteroaromatic compounds as PI3 kinase modulators and methods of use
CA2876246C (en) Substituted pyrazolone compounds and methods of use
CA2898294C (en) Heteroaromatic compounds as pi3 kinase modulators
WO2014022128A1 (en) Pi3 kinase modulators and methods of use
WO2014089324A1 (en) Substituted cyclic compounds and methods of use
WO2014193647A2 (en) Alkenyl compounds and methods of use
WO2014089280A1 (en) Alkynyl compounds and methods of use
HK1210956B (en) Heteroaromatic compounds as pi3 kinase modulators and methods of use
HK1218385B (en) Heteroaromatic compounds as pi3 kinase modulators
BR122021014786B1 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY

Free format text: FORMER OWNER(S): CALITOR SCIENCES, LLC; SUNSHINE LAKE PHARMA CO., LTD.

Owner name: CALITOR SCIENCES, LLC

Free format text: FORMER OWNER(S): CALITOR SCIENCES, LLC; SUNSHINE LAKE PHARMA CO., LTD.

PC Assignment registered

Owner name: CALITOR SCIENCES, LLC

Free format text: FORMER OWNER(S): CALITOR SCIENCES, LLC; NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED

Owner name: SUNSHINE LAKE PHARMA CO., LTD.

Free format text: FORMER OWNER(S): CALITOR SCIENCES, LLC; NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED

PC Assignment registered

Owner name: SUNSHINE LAKE PHARMA CO., LTD.

Free format text: FORMER OWNER(S): CALITOR SCIENCES, LLC; SUNSHINE LAKE PHARMA CO., LTD.